Schizophrenia
Conditions
Interventions
PPLAI group:PP1M (Invega Sustenna): Patients received PP1M 150 mg eq and 100 mg eq in the deltoid muscle on days 1 and 8, respectively. After one month, according to the patients tolerance and efficac
PP oral medication group:Usage and dosage of paliperidone extended-release tablets: refer to the usage and dosage of drug instructions
Sponsors
Children and Adolescent Psychology Department of Tianjin Anding Hospital
Eligibility
Sex/Gender
All
Age
12 Years to 17 Years
Inclusion criteria
Inclusion criteria: 1) Between 12-17 years old, weighing 29kg; 2) Meet the diagnostic criteria of DSM-5 for schizophrenia; 3) Total score of PANSS exceeds 40; 4) Willing and able to complete the questionnaire independently; 5) Be able to complete the study visit required by the protocol; 6) The subject and the legal representative voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1) The main effective diagnosis of DSM-5 non-schizophrenia; 2) Previous or current presence of any serious or unstable physical disease; 3) Previous nerve blocker malignant syndrome (NMS) or delayed motor disorder; 4) History of paliperidone resistance, defined as the sufficient course of treatment recorded in the history; 5) Subjects with known or suspected allergy or intolerance to paliperidone or any of its excipients; 6) Previous or current use of clozapine in treatment-refractory schizophrenia; 7) With 2 or more antipsychotic drugs (unified with combined drugs, whether patients with multiple antipsychotics can be converted to paliperidone molecular monotherapy) 8) Unable to provide the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PANSS;PSP;CGI-S; | — |
Countries
China
Contacts
Public ContactSun ling
Tianjin Anding Hospital
Outcome results
None listed